CANCER

Personalized flies

Bangi, E. et al Sci. Adv. 5, eaav6528 (2019)

Personalized approaches to study drug responses in human tumors may soon have a new animal option for preclinical drug testing and screening: the fruit fly. Researchers at the Icahn School of Medicine at Mt. Sinai recently reported on patient-customized transgenic Drosophila that they used to screen drugs with the potential to treat treatment-resistant metastatic KRAS-mutant colorectal cancer.

The team genotyped a 53-year old male patient’s colon tumor to determine its mutation profile. Nine mutations were then recreated with a GAL4/UAS vector in othologous genes in the fly hindgut. The transgenic flies were dosed with different existing drugs to see which, if any, improved survival. The most promising combination—trametinib plus zoledronate—was then administered to that original patient, leading to stable improvements for 11 months.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Ellen P. Neff.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Neff, E.P. Personalized flies. Lab Anim 48, 199 (2019). https://doi.org/10.1038/s41684-019-0343-5

Download citation

Search

Sign up for the Nature Briefing newsletter for a daily update on COVID-19 science.
Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing